» Articles » PMID: 16231364

Adipokines in NASH: Postprandial Lipid Metabolism As a Link Between Adiponectin and Liver Disease

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2005 Oct 19
PMID 16231364
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating levels of four adipokines (adiponectin, TNF-alpha, leptin, and resistin) and the postprandial lipid and adiponectin responses to an oral fat load were assessed in 25 non-obese, non-diabetic patients with biopsy-proven nonalcoholic steatohepatitis (NASH) and correlated with metabolic indices and liver histology. Circulating adiponectin was lower in NASH compared with controls (5,476 +/- 344 vs. 11,548 +/- 836 ng/mL; P = .00001) and on multiple regression analysis correlated negatively with liver steatosis, necroinflammation (OR = 5.0; P = .009), and fibrosis (OR = 8.0; P = .003). The magnitude of postprandial lipemia was significantly higher in NASH than in controls and was related to fasting adiponectin (beta = -0.78; P = .00003). Controls showed a significant increase in serum adiponectin in response to the fat load, whereas patients with NASH showed a slight decrease. Postprandial free fatty acids response correlated inversely with adiponectin response in both groups and independently predicted the severity of liver steatosis in NASH (beta = 0.51; P = .031). In conclusion, hypoadiponectinemia is present before overt diabetes and obesity appear and correlates with the severity of liver histology in NASH. Impaired postprandial lipid metabolism may be an additional mechanism linking hypoadiponectinemia and NASH and posing a higher cardiovascular risk to these subjects. The mechanism(s) underlying these differences are unknown, but the type of dietary fat seems to play a role. These findings may have important pathogenetic and therapeutic implications in both liver and metabolic disease.

Citing Articles

An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis.

Jiang K, Bao J, Lou Z, Liu F, Xu K, Kwan H Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006040 PMC: 11859937. DOI: 10.3390/ph18020227.


Co-Morbid Hypothyroidism and Liver Dysfunction: A Review.

Yorke E Clin Med Insights Endocrinol Diabetes. 2024; 17:11795514241231533.

PMID: 38348020 PMC: 10860496. DOI: 10.1177/11795514241231533.


Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria.

Pan J, Ding Y, Sun Y, Li Q, Wei T, Gu Y J Clin Med. 2023; 12(6).

PMID: 36983127 PMC: 10051925. DOI: 10.3390/jcm12062126.


Emerging role of lipophagy in liver disorders.

Nazeer B, Khawar M, Khalid M, Hamid S, Rafiq M, Abbasi M Mol Cell Biochem. 2023; 479(1):1-11.

PMID: 36943663 DOI: 10.1007/s11010-023-04707-1.


Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs-EBP interaction recover NAFLD through enhancing mitochondrial function in mice.

Song N, Xu H, Wu S, Luo S, Xu J, Zhao Q Acta Pharm Sin B. 2023; 13(2):542-558.

PMID: 36873175 PMC: 9978995. DOI: 10.1016/j.apsb.2022.10.003.